|
|
 |
|
Viewing report
|
|
 |
 |
Biopharmaceuticals - Current Market Dynamics and Future Outlook
BioStrategy, May 2005, Pages: 66
The biopharmaceutical market has come along way since 1982 when the first biopharmaceutical product, recombinant human insulin, was launched. Over 130 such products are currently being marketed around the world including thirteen blockbuster drugs.
The global market for biopharmaceuticals, which is currently valued at US$48 billion, has been growing at an impressive compound annual growth rate of 19% over the previous five years.
With over one third of all pipe-line products in active development are biopharmaceuticals, this segment is set to continue outperforming the total pharmaceutical market and could easily reach US$100 billion by the end of the decade.
This report reviews the current status of the market of biopharmaceuticals, highlights the differences between regional markets, maps leading biopharmaceutical classes and discusses the different windows of opportunities opening in this market including the potential for biogenerics. The report provides figures of market size, growth rates and historical evolution of the global, North American, European and Japanese biopharmaceutical markets.
It also provides sales and growth rate figures for the following leading biopharmaceutical products with combined revenue of over US$38 billion: Epogen / Aranesp, Eprex / Procrit / Erypo, Remicade, Neupogen / Neulasta, MabThera / Rituxan, Avonex, Enbrel, Pegasys / Roferon A, Peg-Intron / Intron A, Betaferon / Betaseron, Humulin / Humalog, Rebif, Synagis and Herceptin.
Erythropoietins with a market size of over US$11 billion and rising, Monoclonal Antibodies with a market size approaching US$10.2 billion and a stratospheric growth rate, Human Insulin and analogs, Interferon and Colony Stimulating Factors are some of the main biopharmaceutical classes profiled in this report.
Each class profile contains a thoughtful market dynamics analysis including size, evolution, growth rate, leading participants’ market shares and highlights of the strategic opportunities relating to that particular segment of the market.
The report also discusses the biopharmaceutical market outlook, growth potential, attractive areas of growth, technological innovations, products in development and biogenerics opportunities.
Written with the senior executive needs in mind, Biopharmaceuticals – Current Market Dynamics & Future outlook, is a must read for pharmaceutical and medical biotech professionals interested in high growth area therapeutics.
Customers who bought this item also bought
Biopharmaceuticals in South East Asia
Global Biopharmaceutical Contract Manufacturing Markets
Indian Biopharmaceuticals Industry Report
Who’s Developing What in Global Biopharmaceuticals?
Growth Opportunities in Global Pultrusion Market 2009-2014: Global Market Outlook
Strategic Analysis of the U.S. Biopharmaceuticals Market
PharmaVitae 2004: Chiron Global Analysis
Protein Drug Delivery: Penetrating a Growth Market
China Biopharmaceutical Industry Report, 2007-2008
China Biopharmaceutical Industry Report, 2007-2008
PharmaVitae 2004: Chiron Global & US Analysis
Therapeutic Monoclonal Antibodies Markets
|
 |
|
|